Japanese Encephalitis News and Research

RSS

Japanese encephalitis (previously known as Japanese B encephalitis to distinguish it from von Economo's A encephalitis) is a disease caused by the mosquito-borne Japanese encephalitis virus. The Japanese encephalitis virus is a virus from the family Flaviviridae. Domestic pigs and wild birds are reservoirs of the virus; transmission to humans may cause severe symptoms. One of the most important vectors of this disease is the mosquito ''Culex tritaeniorhynchus''. This disease is most prevalent in Southeast Asia and the Far East.

Sinovac first quarter sales increase 5.3% to $4.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2011.

13 May 2011

Sinovac reports fourth quarter net sales of $9.1 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its fourth quarter and full year financial results periods ended December 31, 2010.

31 Mar 2011

Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today the unblinding of the Phase I clinical trial results for the adult population for its proprietary inactivated vaccine against human enterovirus 71, which causes hand, foot, and mouth disease.

10 Mar 2011

ITMNs can reduce Japanese Encephalitis transmission to humans

A new study revealed that using treated mosquito nets could drastically reduce the transmission of Japanese Encephalitis to humans.

9 Mar 2011

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today it submitted the application to commence clinical trials for its 13-valent pneumococcal conjugate vaccine (PCV) to China's State Food and Drug Administration (SFDA) on March 3, 2011.

3 Mar 2011

Intercell reports EUR 255.2m net loss for full year 2010

Today Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company's development programs.

1 Mar 2011

Sanofi Pasteur, International Vaccine Institute support Dengue Vaccine Initiative

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI). Sanofi Pasteur and the IVI will aim to raise awareness and to work to move dengue vaccination higher on the global health agenda.

21 Feb 2011

Global Health Consortium to support development of vaccines to control dengue fever

The International Vaccine Institute today announced the launch of the Dengue Vaccine Initiative, in collaboration with the Sabin Vaccine Institute, the Johns Hopkins University, and the World Health Organization, to support development of vaccines to control dengue fever, a widespread and expanding hemorrhagic fever that is endemic in most tropical and subtropical regions of the world.

10 Feb 2011

Inviragen completes memorandum of understanding with Duke-NUS

Inviragen, and the Duke-National University of Singapore Graduate Medical School announced today that they have completed a memorandum of understanding to establish a partnership between the two organizations.

27 Jan 2011

Sinovac's inactivated EV71 vaccine clinical trial against HFMD receives Chinese SFDA approval

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD).

28 Dec 2010

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Intercell AG announced today preliminary clinical results on its investigational Travelers' Diarrhea (TD) Vaccine Patch program and the decision not to pursue further the development of this vaccine candidate. The decision was made following the receipt of results of its randomized and placebo-controlled Phase III study (ELT301) with 2036 travelers from Europe to Mexico and Guatemala as well as the pilot efficacy Phase II trial (ELT209) with 723 travelers from Europe to India.

13 Dec 2010

Vaccine World Summit to be held in New Delhi 1-3 March, 2011

From the 1st to the 3rd of March 2011, vaccine leaders from developing and developed world will meet at Vaccine World Summit in New Delhi. The event will be hosted by IMAPAC, in partnership with DCVMN (Developing Countries Vaccine Manufacturers Network).

8 Dec 2010

Sinovac third quarter sales decrease 7% to $9.6 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2010.

15 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the five manufacturers to supply seasonal influenza vaccine to the citizens of Beijing.

25 Oct 2010

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that Sinovac Biotech (Hong Kong) Ltd., its wholly owned subsidiary company in Hong Kong, has received the Certificate of Drug/Product Registration from the Hong Kong Department of Health for its seasonal influenza vaccine Anflu.

25 Oct 2010

Intercell reports significant increase in second quarter revenue

Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets

17 Aug 2010

Sinovac Biotech second-quarter 2010 sales increase 131% to $10.3 million

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month and six-month periods ended June 30, 2010.

16 Aug 2010

Tamir Biotechnology's three compounds effective show potential for yellow fever

Tamir Biotechnology, Inc.(formerly Alfacell Corporation) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of three of our company's compounds showed in vitro results rarely seen before by the U.S. government for yellow fever.

11 Aug 2010

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

GAVI Alliance's plan to introduce new vaccine projects in the developing world "is under threat amid the international economic downturn," the Financial Times reports. "Subsidies to extend the use of vaccines against rubella, HPV to tackle cervical cancer, cholera and Japanese encephalitis in the developing world are among those likely to be cancelled or delayed," according to GAVI's CEO Julian Lob-Levyt, the newspaper writes.

17 Jun 2010